| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KCNH8 |
| Uniprot No | Q96L42 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 899-1107aa |
| 氨基酸序列 | LSPQQPSRFCSLHSTSVCPSRESLQTRTSWSAHQPCLHLQTGGAAYTQAQLCSSNITSDIWSVDPSSVGSSPQRTGAHEQNPADSELYHSPSLDYSPSHYQVVQEGHLQFLRCISPHSDSTLTPLQSISATLSSSVCSSSETSLHLVLPSRSEEGSFSQGTVSSFSLENLPGSWNQEGMASASTKPLENLPLEVVTSTAEVKDNKAINV |
| 预测分子量 | 26.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KCNH8重组蛋白的虚构参考文献示例(仅供参考，实际文献请通过学术数据库查询)：
---
1. **"Functional Characterization of Recombinant KCNH8 Potassium Channels in Mammalian Cells"**
*Authors: Smith A, et al. (Journal of Molecular Neuroscience, 2020)*
**摘要**: 本研究利用HEK293细胞系统重组表达了KCNH8蛋白，分析了其电生理特性及通道动力学。结果显示KCNH8介导延迟整流钾电流，其激活和失活特性可能参与神经元兴奋性调节。
2. **"KCNH8 Modulates Neuronal Excitability and Synaptic Plasticity in the Hippocampus"**
*Authors: Zhang L, et al. (Neuropharmacology, 2019)*
**摘要**: 通过重组KCNH8蛋白和基因敲除模型，发现KCNH8通过调控钾离子外流影响海马区神经元动作电位发放频率，可能对癫痫和认知障碍具有潜在病理关联。
3. **"Screening of Small Molecule Regulators Targeting Recombinant KCNH8 Channels"**
*Authors: Tanaka K, et al. (Scientific Reports, 2021)*
**摘要**: 开发了一种基于KCNH8重组蛋白的高通量药物筛选平台，鉴定出多个可增强或抑制通道活性的化合物，为神经退行性疾病治疗提供候选分子。
4. **"Structural Insights into KCNH8 Channel Gating by Cryo-EM"**
*Authors: Wang Y, et al. (Nature Structural Biology, 2022)*
**摘要**: 通过冷冻电镜解析了重组KCNH8蛋白的闭合和开放状态结构，揭示了其电压感应域(VSD)的动态构象变化机制，为靶向设计通道调节剂提供结构基础。
---
**注**：以上文献为示例，实际研究需查询PubMed、Google Scholar等平台，或参考KCNH8相关基因功能、离子通道研究领域的论文。
**Background of KCNH8 Recombinant Protein**
KCNH8. a member of the potassium voltage-gated channel subfamily H (EAG), encodes the Ether-à-go-go 2 (EAG2) protein, a key regulator of neuronal and cardiac excitability. This channel contributes to the delayed rectifier potassium current, influencing action potential repolarization and cellular electrical stability. Dysregulation of KCNH8 has been linked to neurological disorders, epilepsy, and certain cancers, highlighting its physiological and pathological relevance.
Recombinant KCNH8 protein is engineered using heterologous expression systems (e.g., HEK293 or CHO cells) to produce functional ion channels for structural and functional studies. Its production enables detailed investigation of channel gating, ligand interactions, and modulation by signaling pathways. Researchers utilize purified recombinant KCNH8 to screen potential therapeutics targeting channelopathies or overactivity in diseases like glioblastoma, where EAG2 overexpression promotes tumor progression.
Recent studies focus on cryo-EM structures of KCNH8 to elucidate its unique voltage-sensing and pore domains, distinguishing it from related channels like hERG (KCNH2). These insights aid in designing selective inhibitors or activators. Additionally, recombinant KCNH8 serves as a tool to study post-translational modifications (e.g., phosphorylation) affecting channel trafficking and activity. Despite challenges in achieving stable, high-yield expression, advancements in protein engineering continue to enhance its utility in both basic research and drug discovery.
Overall, KCNH8 recombinant protein bridges molecular understanding and therapeutic innovation, offering a pathway to address diseases linked to potassium channel dysfunction.
×
